- AstraZeneca, GSK Merck, Novartis, Pfizer and Roche lead pharmaceutical licensing market
- Strong demand for licensing of oncology therapies
- Small companies with promising molecules at early stage development are key licensing targets for big pharma
LONDON--(BUSINESS WIRE)-- Pharmaceutical licensing agreements are proving to be a cost-effective way of acquiring new molecules for drug discovery and development, according to a new report available on companiesandmarkets.com. Most pharmaceutical in-licensing activity is conducted by large pharmaceutical companies who are in a strong position to commercialize novel therapeutics.
Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
Research and development in the pharmaceutical industry is incredibly expensive and time consuming, therefore pharmaceutical companies are constantly seeking ways of cutting costs and speeding up the process. By in-licensing potential products, pharmaceutical companies can compensate for reduced expenditure on R&D, while also offsetting the limitations of their existing product pipelines which have been subdued by budgetary restraints in recent years.
By acquiring the rights to novel molecules developed by universities and small companies - or the companies themselves in some instances - large pharmaceutical companies are able to remain competitive and minimise the risk of failure associated with drug development.
2012 marks the year in which a number of blockbuster patents will expire, leaving several pharmaceutical companies in a vulnerable position as generic alternatives encroach on their market share.
In-licensing also provides pharmaceutical companies with the opportunity to enter into markets where they have no existing presence, or present distinct opportunities for growth. The unmet need within the oncology/cancer market is particularly attractive to big pharma, as is the monoclonal antibodies segment.
Published in September 2011, the report provides 153 pages of pharmaceutical licensing analysis, split by value, type, geography, therapy area and phase for the period 2006-2010. The report discusses the licensing lifecycle, in-licensing and out-licensing trends, important deals and the drivers which encourage licensing activity in the pharmaceutical sector.
The pharmaceutical licensing activities of the following companies are examined at length within this report: GlaxoSmithKline; J&J Roche; Abbott; Eli Lilly; Novartis; Sanofi; Takeda; Pfizer; Bristol-Myers Squibb; Boehringer-Ingelheim; Merck & Co.; Bayer; AstraZeneca; Astellas; Daiichi-Sankyo; Teva Pharma; Eisai; Baxter and Amgen.
Companies & Markets
London (UK): +44 (0) 203 086 8600
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Practice Management Health Pharmaceutical Other Health